Skip to main content
Sanofi India Ltd logo

Sanofi India Ltd — Investor Relations & Filings

Ticker · SANOFI ISIN · INE058A01010 LEI · 335800VFWLEY5V6PYH80 BSE.NS Manufacturing
Open in API
Filings indexed 1,554 across all filing types
Latest filing 2021-11-26 Capital/Financing Update
Country IN India
Listing BSE.NS SANOFI

About Sanofi India Ltd

https://www.sanofi.in

Sanofi India Ltd focuses on the development, manufacturing, and marketing of a wide range of pharmaceutical products and healthcare solutions. The company operates across several therapeutic areas, including diabetes, cardiology, thrombosis, central nervous system disorders, and consumer healthcare. Its product portfolio includes established brands such as Lantus, Allegra, Combiflam, Amaryl, Avil, and Enterogermina. The organization prioritizes chronic disease management and acute care through a combination of prescription medicines and over-the-counter treatments. By integrating global research capabilities with local manufacturing excellence, the company provides specialized medical solutions aimed at improving patient health outcomes and addressing unmet medical needs.

Recent filings

Filing Released Lang Actions
Updates
Capital/Financing Update Classification · 95% confidence The document is a formal letter addressed to stock exchanges regarding the divestment of certain business assets (brands Soframycin® and Sofradex®) by Sanofi India Limited. It details the transaction terms, valuation, buyer information, and regulatory disclosures under SEBI Listing Obligations. The content focuses on a corporate transaction involving asset sale and related approvals by the Board, with no financial statements or earnings data presented. This fits the category of a Capital/Financing Update as it informs about a significant business transaction affecting company assets and operations. The document length and detail confirm it is not a brief announcement or a report publication notice, but a substantive update on financing-related corporate activity.
2021-11-26 English
Please find enclosed announcement related to - Divestment of Soframycin® and Sofradex® businesses of the Company which is self explanatory for your information and records
Capital/Financing Update Classification · 95% confidence The document is a formal letter addressed to stock exchanges regarding the divestment of certain business assets (brands Soframycin® and Sofradex®) by Sanofi India Limited. It details the transaction terms, valuation, buyer information, and regulatory disclosures under SEBI Listing Obligations. The content focuses on a corporate transaction involving asset sale and related disclosures, not a financial report, earnings release, or management discussion. It is an announcement of a capital transaction and related regulatory disclosure. Therefore, the document fits best under Capital/Financing Update (CAP) as it updates on a significant asset sale and related financial consideration.
2021-11-26 English
Resignation
Board/Management Information Classification · 100% confidence The document is a formal notification addressed to stock exchanges about the resignation of a Non-Executive Director, Mr. Cyril Grandchamp-Desraux, citing Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. It is a clear announcement of a change in the company's board of directors. The document is short (1240 characters) and does not contain financial data or detailed reports. Therefore, it fits the category of Board/Management Information (MANG).
2021-11-24 English
As required under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we would like to inform you that the Company has received a letter today, ....
Board/Management Information Classification · 100% confidence The document is a formal notification addressed to stock exchanges about the resignation of a Non-Executive Director, Mr. Cyril Grandchamp-Desraux, citing Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. It is an announcement of a change in the company's board of directors. The document is short (1240 characters) and does not contain financial data or reports. Therefore, it fits the category of Board/Management Information (MANG).
2021-11-24 English
Loss of Share Certificates
Regulatory Filings Classification · 95% confidence The document is a formal letter addressed to stock exchanges regarding the issuance of duplicate share certificates due to lost or misplaced original certificates. It references compliance with SEBI Listing Obligations and Disclosure Requirements, Regulation 39(3). The content is about share certificate replacement and does not contain financial data, earnings, management changes, or other report types. It is an official regulatory announcement related to share certificates but does not fit into categories like Share Issue/Capital Change or Transaction in Own Shares since it is about duplicate certificates. The best fitting category is Regulatory Filings (RNS) as a general regulatory announcement that does not fit other specific categories. The document length is short (1308 characters), consistent with a regulatory filing rather than a full report.
2021-11-18 English
Pursuant to Regulation 39 (3) of SEBI (Listing Obligations and Disclosure Requirements), Regulations 2015, we would like to inform you that the Company has issued duplicate share certificates ....
Regulatory Filings Classification · 95% confidence The document is a formal letter addressed to stock exchanges regarding the issuance of duplicate share certificates due to lost or misplaced original certificates. It references compliance with SEBI (Listing Obligations and Disclosure Requirements) Regulations, specifically Regulation 39(3). The content is about share certificate replacement and does not contain financial data, earnings, management discussion, or any report publication. It is an official regulatory announcement related to shareholding records but does not fit into categories like share issue, capital change, or director dealings. Given the nature and length of the document, it best fits under Regulatory Filings (RNS), which is the fallback for miscellaneous regulatory announcements that do not fit other categories.
2021-11-18 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.